Dept. of Psychiatry, University of Muenster, Germany.
Eur Neuropsychopharmacol. 2010 May;20(5):301-9. doi: 10.1016/j.euroneuro.2009.09.006. Epub 2009 Oct 24.
Neuropeptide Y (NPY) has been found to play a role in the pathomechanism of both anxiety and depression. Thus, NPY is a promising candidate in the investigation of the clinical phenotype of "anxious depression". Five NPY gene variants were investigated for an influence on antidepressant treatment response in a sample of 256 patients with depression. Additionally, NPY gene impact on amygdala activation during facial emotion processing was analyzed in a subsample of 35 depressed patients. Particularly in anxious depression, the less active NPY rs16147 -399C allele conferred slow response after 2weeks and failure to achieve remission after four weeks of treatment. The rs16147 C allele was further associated with stronger bilateral amygdala activation in response to threatening faces in an allele-dose fashion. The present results point towards a possible influence of functional NPY gene variation on antidepressant treatment response in anxious depression, potentially conveyed by altered emotional processing.
神经肽 Y（NPY）已被发现与焦虑和抑郁的发病机制有关。因此，NPY 是研究“焦虑性抑郁”临床表型的一个很有前途的候选者。在 256 名抑郁症患者的样本中，研究了 5 种 NPY 基因变异对抗抑郁治疗反应的影响。此外，在 35 名抑郁症患者的亚样本中分析了 NPY 基因对面部情绪处理期间杏仁核激活的影响。特别是在焦虑性抑郁中，活性较低的 NPY rs16147-399C 等位基因在治疗 2 周后反应较慢，在治疗 4 周后无法达到缓解。rs16147C 等位基因与威胁面孔时双侧杏仁核更强的激活呈等位基因剂量依赖性相关。这些结果表明，功能性 NPY 基因变异可能对焦虑性抑郁的抗抑郁治疗反应有影响，可能通过改变情绪处理来传递。
